Harbinger slashes stake by 7.3% in Medivation

By E. Janene Geiss

Philadelphia, Oct. 22 - Harbinger Capital Partners Master Fund I, Ltd. decreased its holdings by 7.3% in Medivation, Inc. as of Oct. 20, according to an SC 13G/A filing with the Securities and Exchange Commission.

Harbinger reported a 2.7% passive stake, representing 802,205 shares.

It previously reported a passive stake of 10%, or an investment of 2,875,543 shares, on Nov. 9, 2007, according to an earlier SC 13G filing.

Medivation is San Francisco-based biopharmaceutical company that acquires technologies in the late pre-clinical development phase.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.